To validate the Illumina TruSight Tumor (TST) NGS panel for clinical usage we analyzed 81 lung cancers, cutaneous malignant melanomas (CMMs) and colon cancers with existing clinical mutation data for hotspot mutations in EGFR, KRAS, NRAS, and BRAF (Table 1) (in addition to our previous validation of TST in a research setting, [9]). This evidence concerns the gene NRAS and colonic neoplasm.